Cargando…

Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational and interventional studies. The goal of this study was to determine if proxalutamide, an androgen receptor antagonist, could be an effective treatment for men with COVID-19 in an outpatient setting. A randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCoy, John, Goren, Andy, Cadegiani, Flávio Adsuara, Vaño-Galván, Sergio, Kovacevic, Maja, Situm, Mirna, Shapiro, Jerry, Sinclair, Rodney, Tosti, Antonella, Stanimirovic, Andrija, Fonseca, Daniel, Dorner, Edinete, Onety, Dirce Costa, Zimerman, Ricardo Ariel, Wambier, Carlos Gustavo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326462/ https://www.ncbi.nlm.nih.gov/pubmed/34350193 http://dx.doi.org/10.3389/fmed.2021.668698

Ejemplares similares

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
por: Cadegiani, Flavio A, et al.
Publicado: (2021)

Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster
por: Goren, Andy, et al.
Publicado: (2021)

Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial
por: Cadegiani, Flavio A, et al.
Publicado: (2021)

Prevalence of hair shedding among women
por: Kovacevic, Maja, et al.
Publicado: (2016)

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
por: Cadegiani, Flavio A, et al.
Publicado: (2021)

Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients
por: Cadegiani, F.A., et al.
Publicado: (2021)

Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign
por: Wambier, Carlos Gustavo, et al.
Publicado: (2020)

The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort
por: Cadegiani, Flavio A, et al.
Publicado: (2021)

Reply to comment on: The Gabrin sign
por: Wambier, Carlos Gustavo, et al.
Publicado: (2021)

SARS-CoV-2 infection in patients with thyroid disease: a cross-sectional study
por: Nguyen, Cristina, et al.
Publicado: (2021)

Comparative Genomics and Characterization of SARS-CoV-2 P.1 (Gamma) Variant of Concern From Amazonas, Brazil
por: Zimerman, Ricardo Ariel, et al.
Publicado: (2022)

Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)
por: Cadegiani, Flavio A., et al.
Publicado: (2020)

Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
por: Cadegiani, Flavio A., et al.
Publicado: (2020)

Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals
por: Wambier, Carlos Gustavo, et al.
Publicado: (2020)

Remission of Severe Myasthenia Gravis After Massive-Dose Vitamin D Treatment
por: Cadegiani, Flávio Adsuara
Publicado: (2016)

Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
por: Wambier, Carlos Gustavo, et al.
Publicado: (2020)

Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response
por: Qiao, Yuanyuan, et al.
Publicado: (2023)

Time of onset and duration of post-COVID-19 acute telogen effluvium
por: Abrantes, Tatiana F., et al.
Publicado: (2021)

Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis
por: Gu, Yue, et al.
Publicado: (2021)

Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature
por: Yang, Da‐Wei, et al.
Publicado: (2023)

Stay-At-Home Orders Are Associated With Emergence of Novel SARS-CoV-2 Variants
por: Zimerman, Ricardo A, et al.
Publicado: (2021)

Retraction: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Publicado: (2022)

Editorial: New Perspectives on the Endocrinology of Physical Activity and Sport
por: Ackerman, Kathryn E., et al.
Publicado: (2021)

Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Publicado: (2022)

Reply to early-onset effluvium secondary to COVID-19 and body hair effluvium
por: Wambier, Carlos Gustavo, et al.
Publicado: (2022)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated
por: Wambier, Carlos Gustavo, et al.
Publicado: (2020)

Predominance of the SARS-CoV-2 Lineage P.1 and Its Sublineage P.1.2 in Patients from the Metropolitan Region of Porto Alegre, Southern Brazil in March 2021
por: Franceschi, Vinícius Bonetti, et al.
Publicado: (2021)

Dermoscopic Features as Predictors of BRAF Mutational Status and Sentinel Lymph Node Positivity in Primary Cutaneous Melanoma
por: Filipović, Nika, et al.
Publicado: (2021)

Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo
por: Gianfaldoni, Serena, et al.
Publicado: (2018)

Diagnosis of Overtraining Syndrome: Results of the Endocrine and Metabolic Responses on Overtraining Syndrome Study: EROS-DIAGNOSIS
por: Cadegiani, Flavio Adsuara, et al.
Publicado: (2020)

“MATH+” Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale
por: Kory, Pierre, et al.
Publicado: (2022)

Are night shift workers at an increased risk for COVID-19?
por: Lim, Rachel K., et al.
Publicado: (2020)

The expression of syndecan-1 in psoriatic epidermis
por: Tomas, Davor, et al.
Publicado: (2008)

NOTALGIA PARESTHETICA
por: Šitum, Mirna, et al.
Publicado: (2018)

Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial
por: Yang, Dawei, et al.
Publicado: (2023)

Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework
por: King, Brett A., et al.
Publicado: (2022)

Technetium and blood extravasation before gammagraphy: a case report
por: Vano-Galvan, Sergio, et al.
Publicado: (2009)

Hair and scalp‐related disorders are a trending topic in dermatology, with a significant increase in number of consultations in the last decade
por: Vano‐Galvan, Sergio
Publicado: (2022)

DIFFERENTIAL DIAGNOSIS OF CHEILITIS – HOW TO CLASSIFY CHEILITIS?
por: Lugović-Mihić, Liborija, et al.
Publicado: (2018)

A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage
por: Skuhala, Tomislava, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rv8pqf6jtimnn6cf32kkmv7muj